Table 2 Recommendations to determine antimalarial efficacy in uncomplicated P. falciparum infection in pregnancy (beyond current WHO standards for non-pregnant patients)

Report the following

 Gestational age

  Gestational age in weeks

  Method of gestational age estimation and when it was obtained

  The proportion of pregnancies with different methods of gestational age estimation (optional)

  Quality control measures (desirable)

 Parity and gravidity

  Parity and gravidity

 Duration of follow-up

  Pragmatically at least adhere to the WHO guidelines for reporting outcomes on 28–42 days (optimal recommendations being likely to emerge from individual patient data analysis)

  Continue parasitological follow-up until delivery

  Record all episodes of P. falciparum and non-falciparum malaria

 Other antimalarials

  Document the type, date of administration and supervision (or self-taken) of IPTp

  Document the type, date of administration and supervision (or self-taken) of cotrimoxazole

  In the context of a RCT supervised treatment, treat parasite reappearance in each arm with the same efficacious regimen which should be different to the primary treatment (and preferably given under supervision)

 Placental malaria and congenital malaria

  Placental malaria and congenital malaria should be assessed as part of assessment of efficacy (desirable)

  PCR genotyping should be assessed for placental and congenital malaria and compared to the previous malaria infections during the pregnancy (desirable)